Total Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests

Aetna considers total body photography (TBP) and dermoscopy medically necessary for evaluation of patients with a personal or close family history of atypical/dysplastic nevi, melanoma, or non‑melanoma skin cancers, with repeat studies generally not required more often than every 24 months. TBP/dermoscopy for other indications is considered experimental/investigational and not covered, as are computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate), skin‑surface mRNA collection (Mind.Px), and hand‑held fluorescent molecular imaging (Orlucent).

"Orlucent fluorescent molecular imaging: 'Currently, there is a lack of evidence in the effectiveness of fluorescent molecular imaging (the Orlucent system) for evaluation of a mole’s transition to ..."

Sign up to see full coverage criteria, indications, and limitations.